Individual and combined anti-trypanosomal effects of arteether and diminazene aceturate in the treatment of experimental Trypanosoma brucei brucei infection in rats

Tobias Nnia Egbe-Nwiyi, Samson Eneijo Abalaka, Nuhu Abdulazeez Sani, Oremeyi Zainab Tenuche and Idoko Sunday Idoko

Department of Veterinary Pathology, Faculty of Veterinary Medicine, University of Abuja, Abuja, Nigeria.

Corresponding author: Samson Eneijo Abalaka, e-mail: samson.abalaka@uniabuja.edu.ng

Co-authors: TNE: egbetoby@gmail.com, NAS: nnuh.sani@uniabuja.edu.ng, OZT: tenuche.oremeyi@uniabuja.edu.ng, ISI: idoko.sunday@uniabuja.edu.ng

Received: 17-04-2020, Accepted: 20-07-2020, Published online: 11-09-2020

doi: www.doi.org/10.14202/vetworld.2020.1858-1862 How to cite this article: Egbe-Nwiyi TN, Abalaka SE, Sani NA, Tenuche OZ, Idoko IS (2020) Individual and combined anti-trypanosomal effects of arteether and diminazene aceturate in the treatment of experimental Trypanosoma brucei brucei infection in rats, Veterinary World, 13(9): 1858-1862.

Abstract

Aim: Trypanosomosis is a vital protozoan disease of man and animals with devastating consequences in the tropical parts of the world, necessitating the investigation of the effects of diminazene aceturate (DA) and arteether (AR) on Trypanosoma brucei brucei experimental infection in rats.

Materials and Methods: We used a total of 98 rats, which were divided into 14 groups (A-N) of seven rats each over 36 days after acclimatizing them. We administered 1×10^6 trypanosomes to the infected groups (B-N) with Group A as the unexposed control rats. Groups C-F became the infected and treated rats with 3.5 mg/kg, 7.0 mg/kg, 10.5 mg/kg, and 14.0 mg/kg of DA while Groups G-J became the infected and treated rats with 0.01 ml/kg, 0.02 ml/kg, 0.03 ml/kg, and 0.04 ml/kg of AR. Groups K-N became infected and treated rats with DA and AR combinations at similar doses.

Results: Parasitemia suppression occurred in Groups G-J only but became cleared in Groups C-F and K-N. Survival time varied significantly (p<0.05) between Group B and the other infected groups. We recorded anemia in all the infected rats while significant (p<0.05) splenomegaly and hepatomegaly occurred in Groups G-J only compared to the other groups.

Conclusion: AR did not inhibit or potentiate the anti-trypanosomal efficacy of DA, and therefore, it is comparatively less effective in combating T. brucei infection at the present doses and treatment regimen.

Keywords: albino rats, arteether, clinicopathology, diminazene aceturate, Trypanosoma brucei brucei.

Introduction

Trypanosomosis is a serious tsetse fly-borne protozoan parasite disease that affects humans and animals [1]. African animal trypanosomosis reportedly causes poor milk yield, poor hair coat, emaciation, anemia, anorexia, intermittent fever, lethargy, infertility, ascites, abortion, and death of the affected animal if it is not correctly treated [2]. There are many species of trypanosomes, but the dominant pathogenic species affecting animals are Trypanosoma vivax, Trypanosoma congolense, Trypanosoma simiae, Trypanosoma godfreyi, and Trypanosoma brucei rhodesiense, and Trypanosoma brucei gambiense cause human African trypanosomosis or sleeping sickness [4]. However, T. brucei affects tissues mainly. The control of animal trypanosomosis has become a major problem as the parasites exhibit antigenic variation, thereby posing a significant threat to livestock vaccination [5]. There is also drug resistance in some cases of animal trypanosomosis [6]. The use of trypanotolerant animals, chemotherapy, and tsetse control is some of the ways advocated for the elimination of animal trypanosomosis [7-9].

Animal trypanosomosis responds to many treatment drugs, among which is diminazene aceturate or DA (Berenil®, Hoechst, Germany) as a conventional trypanocide so far although relapses have been reported [6,10]. Plasmodium falciparum, including Plasmodium vivax, Plasmodium knowlesi, Plasmodium ovale, and Plasmodium malariae, is a protozoan parasite that causes malaria in humans [11]. Therefore, protozoan parasites cause both trypanosomosis and plasmodosis of animals and human beings [12], among others. Drugs such as amodiaquine hydrochloride (Camoquine®, Pfizer, Germany), pyrimethamine and sulfamethoxy pyrazine (Metakelfin®, Pfizer, Germany), chloroquine phosphate, sulfadoxine and pyrimethamine (Fansidar®, Swipha, Nigeria), and artesunate (Rekmal®, Lincoln Pharmaceuticals, Ltd., India) have shown effectiveness in the treatment of plasmodosisis. However, they are weak in the treatment of trypanosomosis [2,13]. Arteether or AR (Artebeta®, Swiss Parenterals, Gujarat, India) is the ethyl ether derivative of dihydroartemisinin [14] as well as a semi-synthetic derivative of artemisinin,
which is a natural plant product of the Chinese plant Artemisia annua [15]. Artemisinins reportedly inhibit the in vitro growth of Trypanosoma cruzi and T. brucei rhodesiense [16] even as chloroquine-resistant human plasmodosis responds well to it [17].

Despite the reported effects of artemisinins in human trypanosomosis and plasmodosis, little is known about its effects in animal trypanosomosis hence the present study. Besides, the presence of any comparative trypanocidal effects in animals over the conventional trypanocidal DA can easily be exploited for meaningful animal production. Therefore, the essence of this study was to ascertain the anti-trypanosomal effects of AR and DA each and together in the treatment of experimental T. brucei brucei infection in rats.

**Materials and Methods**

**Ethical approval**

We carried out the work as approved by the University of Abuja Ethics Committee on Animal Use with Reference No.: UAECAU/2020/003.

**Study period and location**

The study was conducted from January to March 2020 at the University of Abuja, Abuja, Nigeria.

**Experimental animals**

We used 98 healthy adult albino rats of both sexes weighing between 180 and 200 g obtained from the Nigerian Institute for Trypanosomosis Research (NITR), Vom, Nigeria, for the experiment. The 2 weeks laboratory-conditioned rats were randomly divided into 14 groups of seven rats, fed with commercial grower mash (ECWA Feeds Ltd., Jos, Nigeria), and housed in clean cages at ambient temperature (30-35°C) and water were provided ad libitum throughout the study. The animals were screened for the presence of hemoparasites [18] before the experiment started.

**Trypanosomosis stock and inoculation**

The obtained T. brucei brucei (Federer strains) from NITR, Vom, Nigeria, were serial passages in rats to maintain the parasites. We injected 1 ml of phosphate-buffered saline solution (pH 7.4) containing an estimated 1×10⁶ trypanosomes intraperitoneally into each rat in the infected groups (B-N). The rats were examined daily for the presence or appearance of the parasites.

**Test drugs**

We prepared 75 mg of AR (Artebeta®, Swiss Parenterals, Gujarat, India) and 7% DA (Berenil®, Hoechst, Germany) following the manufacturer’s specifications.

**Experimental design**

The experiment involved a total of 98 albino rats that we divided into 13 groups (A-N) of seven rats each. We experimentally infected rats in Groups B-N (91 albino rats) with T. brucei brucei parasites (1×10⁶ trypanosomes) with Group A, containing the uninfected and untreated control albino rats. We administered both drugs separately, intramuscularly. This process involved the administration of DA once at dose rates of 3.5 mg/kg, 7.0 mg/kg, 10.5 mg/kg, and 14.0 mg/kg to each of the albino rat in Groups C-F and AR, at 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, and 0.04 mg/kg to albino rats in Groups G-J, respectively. Groups K-N were infected and treated with DA and AR separately at similar doses. We treated the infected rats on day 12 post-infection (Pi) while AR treatment in Groups G-N continued on days 13-14 Pi.

**Parasitemia and packed cell volume (PCV) determination**

We collected blood samples from the experimental pre-trypanosome and post-trypanosome inoculated rats to determine the level of parasitemia every 2 days by the hematocytometer method. Similarly, we determine the PCV level every 4 days through the microhematocrit method [18].

**Determination of survival time (ST)**

We monitored the experimental rat’s daily Pi until the termination of the work (A-N) or until the day of death (B-N, where applicable) to determine the Pi ST for each rat.

**Organosomatic indices determination**

We sacrificed the rats at the end of the experimental period (for those alive only). Likewise, we immediately conducted a postmortem examination on each of the carcasses (the sacrificed or dead rats), according to standard procedures [19]. We promptly weighed the harvested liver and spleen, and used them to determine the hepatosomatic and splenosomatic index of the experimental rats, as described by Vani and Reddy [20].

**Statistical analysis**

We expressed the data as means ± standard deviations and subjected them to a one-way ANOVA at p<0.05 statistical significance, according to Chatfield [21].

**Results**

We recorded parasitemia in all the infected rats 4 and 6 days Pi (Figure-1) with a mean pre-patent period range of between 4.3±1.0 and 4.6±1.0 days that did not differ significantly (p>0.05) among the infected groups (B-N). However, we observed a gradual rise in parasitemia in the infected rats (B-N) from day 6 Pi until it peaked on day 12 Pi before the treatment commenced.

Groups C-F and K-N became aparasitemic as from day 14 Pi (day 2 post-treatment) until day 36 Pi (day 24 post-treatment) when we terminated the experiment (Figure-1). We recorded a decreased level of parasitemia in Groups G-J from days 14 to 22 Pi (day 9 post-treatment) before rising again from day 24 Pi (day 12 post-treatment). The level of parasitemia increased gradually in Groups G, H, I, and J until day 36 Pi (day 20 post-treatment) when all the rats died. However, we observed suppressed parasitemia in Group J (treated with 0.04 mg/kg Artebeta®) from...
day 28 Pi (day 16 post-treatment) till day 36 Pi (day 24 post-treatment).

We recorded a progressive significantly (p<0.05) different mean ST of 18.0±0.0, 27.1±0.2, 30.7±0.9, and 34.4±0.9 in Groups B, G, H, I, and J, respectively. The ST was significantly (p<0.05) shortest in Group B and longest in Group J, comparable to Groups G and H. The PCV decreased significantly (p<0.05) from day 8 to 14 Pi in all the infected Groups B-N compared the control (Figure-2). However, we recorded increasing PCV after that from day 16 Pi (day 4 post-treatment) before returning to their corresponding pre-infection values by day 36 Pi (day 24 post-treatment). On the other hand, the groups treated with different doses (0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, and 0.04 mg/kg) of AR showed temporary PCV recovery between days 16 and 20 Pi (days 4 and 8 post-treatment) and started decreasing again gradually. All the infected groups (B-N) showed a comparable level of anemia before and after treatment. However, the anemia became more significantly (p<0.05) severe in Group B (infected untreated) compared to those recorded in the infected and AR-treated rats (Groups G, H, I, and J). We observed significant (p<0.05) enlargement of the liver and spleen of Group B rats compared to the infected and AR-treated Groups G-J (Table-1).

**Discussion**

The present study has demonstrated that AR treatment was less effective in the treatment of experimental *T. brucei brucei*-induced trypanosomosis compared to the DA treatment. AR suppressed the level of parasitemia temporarily and prolonged the ST of the
infected rats compared to the level of the parasitemia
and ST in the infected untreated rats (Group B). The
AR suppressed parasitemia observed in this study did
not differ from the findings of earlier workers in rats
infected and treated with amodiaquine hydrochloride,
pyrimethamine, and sulfamethoxy pyrazine, chloro-
quine phosphate, sulfadoxine and pyrimethamine, and
artesunate [13]. The non-clearance of trypanosomes
from the peripheral blood of rats infected with try-
panosomes and treated with AR could be due to insuf-
cient dose administration because artemisinins have
reportedly inhibited in vitro growth of T. cruzi and
T. brucei rhodesiense [16].

Diminazene aceturate has shown that it is a
reliable trypanoside as it cleared the parasites from
the peripheral blood of the treated infected rats
(Groups C-F). However, there are reports of observ-
able relapses following infection with different strains
of trypanosomes that is treated with DA [6,22].
Similarly, the combined AR and DA administra-
tion also cleared the trypanosomes from the periph-
eral blood of the infected and treated rats with both
substances. However, the effectiveness of the combi-
nation therapy might be attributable to its DA compo-
nents rather than to its AR component. Such efficacy
might be due to either inhibiting or potentiating the
actions of DA at the different doses by AR. The lack
of synergism between AR and DA in the present study
did not agree with the observations of Egbe-Nwiyi
et al. [13] in rats infected with T. brucei brucei
and treated with 2.4 mg/kg of artesunate and 3.5 mg/kg
of DA. Nevertheless, AR’s inability to clear the para-
site from the peripheral blood agreed with the findings
of earlier workers who used anti-malarial drugs to
treat animal trypanosomosis [2,13].

The observed anemia could have arisen from
either host or parasite-derived mechanisms [23]. The
host-derived mechanism involves massive host cel-
lar response [23], while the parasite-derived factors
involve the release of substances that modify red
blood cell (RBC) to enhance their elimination by the
host [24]. The reduced PCV is usually associated with
the hemolysis-induced acute phase of the anemia [25]
due to the host immune response [26]. However, the
chronic phase of the anemia is usually associated with
hemodilution arising from increased total plasma vol-
ume and the low but physiologically relevant immune
system-induced RBCs sensitization by the host
IgM [26]. Earlier workers have reported similar anemia
in animal trypanosomiasis [27]. The gradual recovery
of the PCV of the combined AR- and DA-treated rats
showed the efficacy of the drugs in clearing trypano-
somes from the peripheral blood as earlier reported [6].

Both the acute and chronic phases of trypano-
some-induced anemia are known to cause the observed
hepatomegaly and splenomegaly [26]. The splenic
enlargement might be due to RBCs sequestration [28].
Igboke and Nwosu [27] reported similar hepatomegaly
and splenomegaly in T. brucei- and Trypanosoma conco-
lense-infected rats. However, they opined that the liver
and the spleen’s mere enlargement did not significantly
(p>0.05) contribute to the development of the observed
anemia. Besides, the increased hepatosomatic and sple-
nosomatic indices of the infected untreated rats (Group
B) indicated the adverse effects of T. brucei infection
in the exposed rats, especially as the phagocytic activi-
ties of these organs are increased [29]. Nevertheless, the
observed significant (p<0.05) reductions in the AR- and
DA-treated groups compared to the infected untreated
control group showed the ameliorative effects of both
therapeutic compounds in affected rats.

**Conclusion**

AR alone suppressed the level of parasitemia
temporarily and prolonged the ST compared to the DA
and AR/DA exposed groups, respectively. AR also did
not inhibit or potentiate the chemotherapeutic activity
of DA based on the evaluated parameters. Similarly,
we did not observe relapse of parasitemia 20 days
post-treatment in the DA alone or combination with
AR-treated rats. Therefore, AR appears to be less
effective in the treatment of trypanosomosis due to
T. brucei (Federer strain) compared to DA. However,
there is a need to evaluate the efficacy of higher dif-
frential therapeutic doses of AR in T. brucei-infected
rats in case a low dose might be responsible for the
observed low efficacy.

**Authors’ Contributions**

TNE: Conceptualization. TNE, SEA, NAS, OZT,
and ISI: Preparation and experimentation. TNE, SEA,
NAS, OZT, and ISI: Results collation, analysis, and
interpretation. TNE: Drafted the manuscript. TNE,
SEA, NAS, OZT, and ISI: Revision, vetting, and
approval of the final manuscript for submission. All
authors have read and approved the final manuscript.

---

**Table 1:** Hepatosomatic and splenosomatic index of *Trypanosoma brucei brucei* infected and Arteether treated albino rats *(n=7).*

| Parameters | Uninfected untreated control | Infected untreated control | Arteether treatment |
|------------|------------------------------|---------------------------|--------------------|
|            |                              |                           | Infected+ Treatment | Infected+ Treatment | Infected+ Treatment | Infected+ Treatment |
|            |                              |                           | (0.01 mg/kg)        | (0.02 mg/kg)        | (0.03 mg/kg)        | (0.04 mg/kg)        |
| HSI        | 9.6±0.4*                     | 5.0±0.8*                  | 5.4±0.8*           | 5.5±0.8*           | 4.8±0.9*           |
| SSI        | 5.9±0.6*                     | 2.9±0.4*                  | 2.7±0.7*           | 2.8±0.4*           | 2.9±0.8*           |

Values in rows with different superscripts differ significantly *(P<0.05)* compared to the uninfected untreated control

n=Number of rats, HSI = Hepatosomatic index; SSI = Splenosomatic index
Acknowledgments
The authors appreciate the technical assistance of Emmanuel Yohanna, Dr. B. U. Shamaki of Veterinary Pharmacology, Yauba Mohammed of Veterinary Parasitology, and Dr. Tijani Abba of Veterinary Pathology of the University of Maiduguri, Maiduguri, Nigeria. The authors did not receive any funds for this study.

Competing Interests
The authors declare that they have no competing interests.

Publisher’s Note
Veterinary World remains neutral with regard to jurisdictional claims in published institutional affiliation.

References
1. World Health Organization. (2020) Trypanosomiasis, Human African (Sleeping Sickness). Available from: https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-sleeping-sickness. Retrieved on 25-03-2020.
2. Egbe-Nwiyi, T.N. and Igawe, P.B. (2013) Anti-trypanosomal effect of Fansidar® alone and its combination with diminazene aceturate in the treatment of experimental Trypanosoma brucei rhodesiense infection in rats. Sahel J. Vet. Sci., 12: 1-5.
3. Isaac, C., Ciosi, M., Hamilton, A., Scullion, K.M., Dede, P., Igbinosa, I.B., Nmorsi, O.P.G., Masiga, D. and Turner, C.M.R. (2016) Molecular identification of different trypanosomatid species and subspecies in tsetse flies of Northern Nigeria. Parasit. Vectors, 9: 301.
4. Centre for Disease Control and Prevention. (2019) Parasites African Trypanosomiasis (also known as Sleeping Sickness). Centre for Disease Control and Prevention, Atlanta, Georgia. Available from: https://www.cdc.gov/parasites/sleepingsickness/biology.html. Retrieved on 25-03-2020.
5. McCulloch, R., Cobbold, C.A., Figueiredo, L., Jackson, A., Morrison, L.J., Mugnier, M.R., Papavasiliou, N., Schnauffer, A. and Matthews, K. (2017) Emerging challenges in understanding trypanosomiasis antigenic variation. Emerg. Top. Life Sci., 1(6): 585-592.
6. Onyeyili, P.A. and Egwu, G.O. (1995) Chemotherapy of African trypanosomiasis: a historical perspective, protological abstracts. CAB Int., 19(5): 230-241.
7. Berti, D., Dinh-Briendier, S.F., Bras-Gonzáles, R., Lemestre, J.J., Jamonneau, V., Solano, P., Jonen, V., Thévenon, S. and Bucheton, B. (2016) Tolerance of trypanosomatids: A threat, or a key for disease elimination? Trends Parasitol., 32(2): 157-168.
8. Lekho, M., Alfaroukh, I., Bucheton, B., Camara, M., Harris, A., Kaba, D., Lumbala, C., Peka, M., Rayaisse, J., Waiswa, C., Solano, P. and Torr, S. (2016) Tsetse control and the elimination of Gambian sleeping sickness. PLoS Negl. Trop. Dis., 10(4): e0004437.
9. Field, M.C., Horn, D., Fairlamb, A.H., Ferguson, M.A.J., Gray, D.W., Read, K.D., De Rycker, M., Torrie, L.S., Wyatt, P.G., Wyllie, S. and Gilbert, I.H. (2017) Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need. Nat. Rev. Microbiol., 15(4): 217-231.
10. Ezeh, I.O., Ugwu, E.N., Enemona, O.V., Oh, C.F., Ibeagwam, C.N., Ezekwokwu, R.C. and Onah, D.N. (2016) Efficacy of repeated doses of diminazene aceturate (Dinazine®) in the treatment of experimental Trypanosoma brucei infection of Albino rats. Iran. J. Vet. Res., 17(2): 124-129.
11. Larson, B. (2019) Origin of Two Most Virulent Agents of Human Malaria: Plasmodium falciparum and Plasmodium vivax. IntechOpen, London. Available from: https://www.intechopen.com/books/malaria/origin-of-two-most-virulent-agents-of-human-malaria-em-plasmodium-falciparum-em-and-em-plasmodium-vi. Retrieved on 26-03-2020.
12. Silva-Barrios, S. and Stüger, S. (2017) Protozoan parasites and Type 1 IFNs. Front. Immunol., 8: 14.
13. Egbe-Nwiyi, T.N., Igwenagu, E., Ndueidem, U.I.T. and Zira, L.T. (2014) The thalidomide derivatives of artesunate and diminazene aceturate in the treatment of experimental Trypanosoma brucei rhodesiense infection in rats. Afr. J. Biomed. Res., 17(1): 9-14.
14. Pareek, A., Nandy, A., Kochar, D., Patel, K.H., Mishra, S.K. and Mathur, P.C. (2006) Efficacy of β-arteether and α/β arteether for treatment of acute Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg., 75(1): 139-142.
15. Konst-Korzenny, E., Ascencio-Aragón, J.A., Niezen-Lugo, S. and Vázquez-López, R. (2018) Artemisinin and its synthetic derivatives as a possible therapy for cancer. Med. Sci., 6(1): 19.
16. Mishina, Y.V., Krishna, S., Haynes, R.K. and Meade, J.C. (2007) Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei Rhodesiense in vitro growth. Antimicrob. Agents Chemother., 51(5): 1852-1854.
17. Centers for Disease Control and Prevention. (2019) Treatment Guidelines: Treatment of Malaria (Guidelines for Clinicians). US Centers for Disease Control and Prevention, Atlanta, Georgia. Available from: https://www.cdc.gov/malaria/resources/pdf/cdliclinicalguidance.pdf. Retrieved on 03-07-2020.
18. Jain, N.C. (1986) Schalm’s Veterinary Haematology. 4th ed. Lea and Febiger, Philadelphia, PA.
19. Igbokwe, I.O. (1989) Post Mortem examination of carcasses. Zaria Vet., 4(2): 145-152.
20. Vant, M.L. and Reddy, K.P. (2000) Effects of Fluoride accumulation on some enzymes of brain and gastrocnemius muscle of mice. Fluoride, 33(1): 17-26.
21. Chatfield, C. (1983) Statistics for Technology. A Course in Applied Statistics. 3rd ed. Chapman and Hall, London. p1-384.
22. Egbe-Nwiyi, T.N., Igwenagu, E., Nwaso, A.T. and Maina, M.M. (2017) Comparison of pathogenicity of relapsed, field and mixed isolates of Trypanosoma brucei rhodesiense in rats. J. Adv. Vet. Anim. Res., 4(1): 97-103.
23. Stijlemans, B., De Baetseller, P., Magez, S., Van Ginderachter, J.A. and Trez, C.D. (2018) African Trypanosomiasis-associated anemia: The contribution of the interplay between parasites and the mononuclear phagocyte system. Front. Immunol., 9: 218.
24. Szempruch, A.J., Sykes, S.E., Kieft, R., Dennison, L., Becker, A.C., Gartrell, A., Martin, W.J., Nakavasu, E.S., Almeida, I.E., Hajduk, S.L. and Harrington, J.M. (2016) Extracellular vesicles from Trypanosoma brucei mediate virulence factor transfer and cause host anemia. Cell, 164(1-2): 246-257.
25. Preston, J.M. and Weilde, B.T. (1976) Studies on African Trypanosomiasis. Final Report to Department of the Army, Report No. DAMD 17-76-G9412. Walter Reed Army Institute of Research, Washington, DC.
26. Amole, B.O., Clarkson, A.B. Jr. and Shear, H.L. (1982) Pathogenesis of anemia in Trypanosoma brucei-infected mice. Infect. Immun., 36(3): 1060-1068.
27. Igboke, I.O. and Nwosu, C.O. (1997) Lack of correlation between Plasmodium falciparum and Plasmodium vivax infections in rats. J. Comp. Pathol., 117(3): 261-265.
28. Das, K.V.K. and Sasidharan, P.K. (2017) Spleen and its disorders in Trypanosome brucei infection in rats. Plasmodium falciparum (2007) Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth. Antimicrob. Agents Chemother., 51(5): 1852-1854.
29. Murray, P.K., Jennings, F.W., Murray, M. and Urquhart, G.M. (1983) Pathogenetic role of immune complexes in Trypanosome brucei infection in rats. PLoS Negl. Trop. Dis., 10(4): e0004437.
30. Trese, M.G., Torr, S., Alfaroukh, I., Tijani, A.Y., Chagers, M., Albert, G., Lumbala, C., Conly, J., Steele, R. and Letsou, J. (2005) Extracellular vesicles from Trypanosoma brucei mediates virulence factor transfer and cause host anemia. Cell, 164(1-2): 246-257.

*********

Veterinary World, EISSN: 2231-0916 1862